- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06140498
Feasibility of a Self-Efficacy Ecological Momentary Intervention (EMA) App (EMA)
This "SeApp" study aims to test a self-efficacy Ecological Momentary Intervention (EMI) in healthy students in the context of COVID-19. EMIs are mostly smartphone-based applications that deliver interventions to people while being engaged in their daily life activities. The app harnesses the power of self-efficacy autobiographical memories (e.g. problem-solving memories, memories of success).
Ecological Momentary Assessments (EMAs) are also incorporated into the study to capture individuals' feelings, affect, and behavior in real time.
Study Overview
Status
Conditions
Detailed Description
This "SeApp" study aims to test a self-efficacy Ecological Momentary Intervention (EMI) in healthy students in the context of COVID-19. EMIs are mostly smartphone-based applications that deliver interventions to people while being engaged in their daily life activities. The app harnesses the power of self-efficacy autobiographical memories (e.g. problem-solving memories, memories of success).
Ecological Momentary Assessments (EMAs) are also incorporated into the study to capture individuals' feelings, affect, and behavior in real time.
Developed by psychologist Dr. Albert Bandura in 1977, the concept of self-efficacy refers to an individual's belief in their ability to perform the necessary actions to manage particular situations. Bandura's theory highlights four major components of self-efficacy, including mastery experiences, socialmodeling, social persuasion, and psychological responses. The app tested here focuses on mastery experiences, which are what individuals gain when they take on a challenge and succeed. The app prompts participants in the daily recall of self-efficacy memories. The project aims to test its feasibility and to investigate how daily self-efficacy and motivation can be enhanced and perceived stress reduced by daily memory-based training via smartphone app.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10011
- The New School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Value on Perceived Stress Scale ≥ 13
- Student
- Owner of a smartphone
Exclusion Criteria:
1. Psychiatric history
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Digital Self-Efficacy Training with 3 trainings daily and Ecological Momentary Assessment
|
Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week
|
Active Comparator: Control
Ecological Momentary Assessment
|
Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General Self-Efficacy
Time Frame: after app completion and 1 month after app completion
|
change in general self-efficacy meeasured using the General Self-Efficacy Scale (GSE, 10 items rated on a 4-point Likert scale with higher scores indicating greater levels of self-efficacy; min=10, max=40)
|
after app completion and 1 month after app completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perceived Stress
Time Frame: after app completion and 1 month after app completion
|
change in perceived stress measured using the Perceived Stress Scale (PSS; 10 items rated on a 0-4 scale with higher scores indicating greater levels of perceived stress; min=0, max=40)
|
after app completion and 1 month after app completion
|
Intolerance of Uncertainty
Time Frame: after app completion and 1 month after app completion
|
change in intolerance of uncertainty measured using the Intolerance of Uncertainty Scale (IUS; 12 items rated on a 5-point Likert scale with higher scores indicating greater intolerance of uncertainty; min=12, max=60)
|
after app completion and 1 month after app completion
|
State and Trait Anxiety
Time Frame: after app completion and 1 month after app completion
|
change in state and trait anxiety measured using the The State-Trait Anxiety Inventory (STAI; 40 items rated on a 4-point Likert scale with a commonly used cutoff score of 40 indicating probable clinical levels of anxiety; min=20, max=80 on the subscales)
|
after app completion and 1 month after app completion
|
Positive and Negative Affect positive and negative affect
Time Frame: after app completion and 1 month after app completion
|
change in positive and negative affect measured using the Positive and Negative Affect Scale (PANAS; 20 items rated on a 5-point Likert scale with 10 items measuring positive affect and 10 items measuring and higher scores indicating greater levels of positive or negative affect; min=10, max=50 on the subscales)
|
after app completion and 1 month after app completion
|
Hopelessness
Time Frame: after app completion and 1 month after app completion
|
change in hopelessness measured using the BHS
|
after app completion and 1 month after app completion
|
Depression
Time Frame: after app completion and 1 month after app completion
|
change in depression measured using the Beck Hopelessness Scale (BDI-II; 20 true and false items with higher scores indicating greater levels of hopelessness)
|
after app completion and 1 month after app completion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ecological Momentary Assessment
Time Frame: through app participation (1 week)
|
change of momentary mood
|
through app participation (1 week)
|
Hope
Time Frame: after app completion and 1 month after app completion
|
change in hope measured using the Adult Hope Scale (AHS; consists of 12 items, and respondents are required to rate each item on an 8-point Likert scale; min=12, max=96)
|
after app completion and 1 month after app completion
|
Satisfaction with Mobile Application
Time Frame: single time point: immediately after the intervention
|
to evaluate usage of app using the User version of the Mobile Application Rating Scale (uMARS; consists of 20 itesm, scores ranges from 1 to 5; the total score could range from 20 to 100, with higher scores indicating a higher overall quality rating for the app)
|
single time point: immediately after the intervention
|
Coronavirus Anxiety Scale
Time Frame: after app completion and 1 month after app completion
|
to evaluate association with coronoavirus anxiety the coronavirus anxiety scale is used (10 items, each rated on a scale of 0 to 4, the total score could range from 0 to 40)
|
after app completion and 1 month after app completion
|
Self-efficacy memories
Time Frame: single time point: baseline
|
exploratory (descriptive) analysis, using no scale
|
single time point: baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2020-96
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Self Efficacy
-
Brigham and Women's HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingFall Injury | Falls | Exercise Self-Efficacy | Falls Self-EfficacyUnited States
-
Central South UniversityCompletedSelf Efficacy | Self-management
-
IRCCS Policlinico S. DonatoNot yet recruitingSelf Efficacy | Self Confidence | Anticoagulants
-
Kolding SygehusCompleted
-
Beni-Suef UniversityUnknown
-
Tuğba SarıCompleted
-
Karolinska InstitutetCompleted
-
Pacific Northwest University of Health SciencesAmerican Association of Colleges of Osteopathic Medicine - AACOMCompleted
-
University of Vic - Central University of CataloniaCompleted
-
Chinese University of Hong KongCompleted
Clinical Trials on Self-Efficacy Training and Ecological Momentary Assessment
-
Psychiatric University Hospital, ZurichRecruitingPsychiatric Disorder | Waiting for PsychotherapySwitzerland
-
University of ZurichRadboud University Medical Center; Universitaire Ziekenhuizen KU Leuven; Johannes...Completed
-
Johns Hopkins UniversityRakai Health Sciences ProgramCompletedEcological Momentary Assessment and Intervention
-
Hôpital le VinatierInstitut National de la Santé Et de la Recherche Médicale, FranceNot yet recruitingGambling Addiction
-
Chestnut Health SystemsNational Institute on Drug Abuse (NIDA)CompletedRecovery | Substance Use Disorder (SUD)United States
-
Penn State UniversityRecruiting
-
Allina Health SystemRecruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
Nantes University HospitalInstitut de Recherche en Santé Publique, FranceCompletedAutism Spectrum DisordersFrance
-
Nationwide Children's HospitalCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingCancer Survivor | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 and other conditionsUnited States